DexCom (DXCM) Set to Announce Earnings on Thursday

DexCom (NASDAQ:DXCM) is set to post its quarterly earnings results after the market closes on Thursday, July 29th. Analysts expect DexCom to post earnings of $0.44 per share for the quarter. DexCom has set its FY 2021 guidance at – EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 29th. The medical device company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The firm had revenue of $505.00 million for the quarter, compared to analyst estimates of $482.67 million. DexCom had a return on equity of 17.86% and a net margin of 25.36%. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of NASDAQ DXCM opened at $446.98 on Thursday. The firm has a 50 day moving average price of $400.94. The stock has a market capitalization of $43.23 billion, a price-to-earnings ratio of 87.64 and a beta of 0.79. DexCom has a 52 week low of $305.63 and a 52 week high of $456.23. The company has a current ratio of 5.70, a quick ratio of 5.22 and a debt-to-equity ratio of 0.89.

A number of research analysts have issued reports on the company. Stephens reissued a “buy” rating and issued a $468.00 price target on shares of DexCom in a report on Thursday, July 1st. Atlantic Securities assumed coverage on DexCom in a report on Thursday, April 15th. They issued an “overweight” rating and a $438.00 price target for the company. Barclays assumed coverage on DexCom in a report on Monday, May 24th. They issued an “overweight” rating and a $500.00 price target for the company. Citigroup boosted their price target on DexCom from $480.00 to $488.00 in a report on Friday, April 30th. Finally, TheStreet downgraded DexCom from a “b-” rating to a “c” rating in a report on Thursday, April 29th. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $466.00.

In related news, EVP Patrick Michael Murphy sold 500 shares of the stock in a transaction on Wednesday, May 26th. The stock was sold at an average price of $350.00, for a total value of $175,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Sumi Shrishrimal sold 1,461 shares of the stock in a transaction on Tuesday, May 25th. The shares were sold at an average price of $354.79, for a total value of $518,348.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,603 shares of company stock valued at $27,159,356. 0.52% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.

Read More: Why do corrections happen?

Earnings History for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with's FREE daily email newsletter.